•
CR
CRNX
Crinetics Pharmaceuticals, Inc.
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
5.68B
Volume
910.25K
52W High
$57.99
52W Low
$24.10
Open
$0.00
Prev Close
$55.69
Day Range
0.00 - 0.00
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Latest News
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
GlobeNewswire Inc.•Jan 4
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
GlobeNewswire Inc.•Dec 3
Why Crinetics Pharmaceuticals Stock Was Sliding on Friday
The Motley Fool•Nov 7
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Oct 10
Is Crinetics Pharmaceuticals Stock a Buy?
The Motley Fool•Sep 28
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday
Benzinga•Sep 26
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga•Sep 26
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFYâ„¢ (Paltusotine) in Acromegaly at ENDO 2025
GlobeNewswire Inc.•Jul 13